Xcel Therapeutics

Xcell Therapeutics is a South Korean biotechnology company specializing in the development and manufacture of chemically defined media for cell and gene therapy (CGT). The company's flagship product line, CellCor, provides serum-free and animal-derived component-free (ADCF) environments for the cultivation of various cell types, including mesenchymal stem cells (MSCs), natural killer (NK) cells, and exosomes. By eliminating the risks associated with fetal bovine serum (FBS) and human-derived components, Xcell Therapeutics aims to standardize cell culture processes and enhance the safety and efficacy of advanced biopharmaceuticals. The company recently went public on the KOSDAQ exchange in 2024 to expand its global footprint and manufacturing capacity.